Sentences with phrase «based tumor therapies»

Not exact matches

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

In the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the body.

This method will facilitate the analysis of patient tumors and the selection of the most appropriate therapy based on the individualized features of each patient's cancer subtype.

The finding, reported by a Stand Up to Cancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone - blocking therapy.

«This indicates that therapies for high - grade gliomas should be personalized, that is, based on the tumor subtype instead of applying one treatment to all patients,» he says.

In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.

The authors conclude that FL118 - based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.

In experiments with mice, the nanoparticle - based therapy not only wiped out the original targeted breast cancer tumors, but metastases in other parts of the body as well.

A University of Colorado Cancer Center study published in the journal Oncogene used next - generation sequencing technologies to perform the most detailed DNA - based analysis to date of 25 commonly used bladder cancer cell lines, allowing researchers to match patient tumors with their closest genetic cell line match, and demonstrated genetic alterations that may make cells more or less sensitive to common therapies.

Although therapies tailored based on genetic alterations in these tumors have been developed, their benefit is usually short - lived.

Therapies based on immune cells, which target particular tumor molecules, are more specific, but they are not effective against a variety of tumors.

These tumor - rejection antigens may provide a basis for precisely targeted anticancer therapy

Physicians will now be able to categorize CNS tumors more precisely into specific risk groups and make therapy decisions on this basis.

The safe use of a stem - cell - based therapy against brain metastasis would require preventing the engineered cells from persisting within the brain, where they could affect normal tissue and possibly give rise to new tumors.

The scientists said that while most therapies are based on the on - size - fits - all model of medicine, «we've long recognized in cancer that every patient's tumor is different.

Platinum - based therapies are being tested in clinical trials for triple - negative breast cancer, and evaluation of tumor - infiltrating lymphocytes is an important factor in determining response to this treatment.

The fusion of these two genes was observed in just three percent of tumors studied, so any therapy based on this particular genetic aberration would apply to only a small subset of glioblastoma patients.

The findings, published online the week of March 21 in the journal Proceedings of the National Academy of Sciences, demonstrate that nanoparticle - based therapies can act as a «precision medicine» for targeting tumors while leaving healthy tissue intact.

Due to the high efficiency of establishing organoid models from different tissues and diseases, such as cancer, organoid technology allows the generation of large living biobanks of tumor organoids that are amenable for middle - throughput drug screens and may allow personalized therapy design, as a complement to cell line and xenograft - based drug studies (7,19).

This specificity in treatment fits with an emerging approach in cancer treatment nationwide, known as personalized medicine, in which the therapies for each patient are selected based on the genes altered in their tumors.

Our researchers have identified a bacterial - based therapy for attacking pancreatic tumors, offering hope in the fight against one of the deadliest cancers.

After enrolling in a clinical trial for genetically based drug therapy, Victor's tumor has shrunk and shows no signs of growth.

select the most effective therapy based on the unique biologic characteristics of the patient and the molecular properties of a tumor or other disease

«Therefore, any potential promising results get diluted because novel therapies are not administered to those select patients who are most likely to respond, based on their tumors» molecular profile.

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low - Dose Metronomic High - Entropy Therapies, Cancer Research (2017).

Working together with a multidisciplinary team of cancer specialists, our department uses highly advanced cancer care techniques including multimodality imagaing for defining tumor volume, state - of - the - art intensity modulated radiation therapy (IMRT), MRI - based treatment planning, and interstitial brachytherapy using high dosage rate treatment.

«Given the importance of stem cell - based transplantation therapies as well as the clinical significance of tumor metastastis to the bone marrow, there is great therapeutic potential in understanding these cellular interactions,» Sipkins said.

Her goal is to define the molecular architecture and functional significance of a niche, determine how tumor growth impacts the niche, learn how benign and malignant cells compete within a niche, and use this knowledge to design precisely targeted anti-cancer treatments that spare normal bone marrow and improve the efficacy of stem cell - based therapies.

Expertise: Interactions of Ionizing and Non-ionizing Radiation with Biological Tissues, Novel Laser - Based Therapeutics for Brain Tumors, Nanoparticle - Based Photothermal Therapy

The Center for Cancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging methods.

Therefore, we hypothesized that NSCs could be used to enhance antibody - based therapies by delivering antibodies to previously inaccessible tumor foci, while minimizing the exposure of normal tissue to the therapeutic agent.

Co-engrafting mice with human tumors that retain the same characteristics and human immune cells, is a new platform to study the relationship between the human immune system and tumors and develop immuno - oncology - based cancer therapies.

Additionally, the greater the number of these trunk neoantigens, the more likely the patient will respond to immune checkpoint inhibitor therapy, an antibody - based intervention that unleashes T cells to attack tumors.

Three - dimensional CT based radiation therapy is performed on all brain tumor patients at ACIC.

There are several different treatments being compared, including: surgery followed by vaccine - based immunotherapy, surgery followed by oncolytic virus therapy, surgery followed by IL - 12 gene therapy and biopsy followed by placement of a specialized catheter system that draws tumor cells out of the brain.

ALA - based photodynamic therapy of TCC in five dogs induced tumor progression free intervals ranging from 4 - 34 weeks.